Advances in the Targeted Therapy of Liposarcoma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2015 Jan 23

PMID 25609980

Citations 21

Authors

Zhonghai Guan

Xiongfei Yu

Haohao Wang

Haiyong Wang

Jing Zhang

Guangliang Li

Jiang Cao

Lisong Teng

Affiliations

Soon will be listed here.

Abstract

Liposarcoma (LPS) is the most common type of soft-tissue sarcoma. Complete surgical resection is the only curative means for localized disease; however, both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. An increasing number of trials with novel targeted therapy of LPS have provided encouraging data during recent years. This review will provide an overview of the advances in our understanding of LPS and summarize the results of recent trials with novel therapies targeting different genetic and molecular aberrations for different subtypes of LPS.

Citing Articles

Extracellular Vesicle - MDM2-DNA as a Potential Liquid Biopsy Biomarker for Disease Identification in Retroperitoneal Liposarcoma.

Calore F, Casadei L, Sarchet P, Fadda P, Nigita G, Coombes K Ann Surg. 2024; .

PMID: 38771951 PMC: 11579277. DOI: 10.1097/SLA.0000000000006345.

Adjuvant Palbociclib May be Associated with Delayed Recurrence in Completely Resected Retroperitoneal Liposarcoma: Results of a Single-Institution Retrospective Cohort Study.

Selby L, Clark E, Liebner D, Chen J, Tinoco G, Bashian E Ann Surg Oncol. 2023; 30(12):7876-7881.

PMID: 37330448 DOI: 10.1245/s10434-023-13692-0.

Three dimensional models of dedifferentiated liposarcoma cell lines: scaffold-based and scaffold-free approaches.

Tahara S, de Faria F, Sarchet P, Calore F, Sharick J, Leight J Hum Cell. 2023; 36(3):1081-1089.

PMID: 36763259 DOI: 10.1007/s13577-023-00865-y.

Cross-flow microfiltration for isolation, selective capture and release of liposarcoma extracellular vesicles.

Casadei L, Choudhury A, Sarchet P, Mohana Sundaram P, Lopez G, Braggio D J Extracell Vesicles. 2021; 10(4):e12062.

PMID: 33643547 PMC: 7887429. DOI: 10.1002/jev2.12062.

Multi-Layer Micro-Nanofluidic Device for Isolation and Capture of Extracellular Vesicles Derived from Liposarcoma Cell Conditioned Media.

Mohana Sundaram P, Casadei L, Lopez G, Braggio D, Balakirsky G, Pollock R J Microelectromech Syst. 2021; 29(5):776-782.

PMID: 33519169 PMC: 7839931. DOI: 10.1109/jmems.2020.3006786.

References

Bennett K, Hackanson B, Smith L, Morrison C, Lang J, Schuller D . Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res. 2007; 67(10):4657-64. DOI: 10.1158/0008-5472.CAN-06-4793. View

Kasibhatla M, Steinberg P, Meyer J, Ernstoff M, George D . Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2007; 5(4):291-4. DOI: 10.3816/CGC.2007.n.007. View

Cheok C, Verma C, Baselga J, Lane D . Translating p53 into the clinic. Nat Rev Clin Oncol. 2010; 8(1):25-37. DOI: 10.1038/nrclinonc.2010.174. View

FREEDMAN D, Wu L, Levine A . Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999; 55(1):96-107. PMC: 11146946. DOI: 10.1007/s000180050273. View

Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler W . C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell. 2001; 8(4):817-28. DOI: 10.1016/s1097-2765(01)00366-5. View

Demetri G, Fletcher C, Mueller E, Sarraf P, NAUJOKS R, Campbell N . Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999; 96(7):3951-6. PMC: 22401. DOI: 10.1073/pnas.96.7.3951. View

Ortega S, Malumbres M, Barbacid M . Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002; 1602(1):73-87. DOI: 10.1016/s0304-419x(02)00037-9. View

Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, Smet E . Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res. 2006; 66(19):9646-55. DOI: 10.1158/0008-5472.CAN-06-0792. View

Worch J, Cyrus J, Goldsby R, Matthay K, Neuhaus J, Dubois S . Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation. Cancer Epidemiol Biomarkers Prev. 2011; 20(3):449-53. PMC: 3051020. DOI: 10.1158/1055-9965.EPI-10-1170. View

10.

Barone M, Crozat A, Tabaee A, Philipson L, Ron D . CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes Dev. 1994; 8(4):453-64. DOI: 10.1101/gad.8.4.453. View

11.

Sleijfer S, Ouali M, Van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Cesne A . Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research.... Eur J Cancer. 2009; 46(1):72-83. DOI: 10.1016/j.ejca.2009.09.022. View

12.

Johnson K, Brown P . Drug development for cancer chemoprevention: focus on molecular targets. Semin Oncol. 2010; 37(4):345-58. DOI: 10.1053/j.seminoncol.2010.05.012. View

13.

Zagars G, Ballo M, Pisters P, Pollock R, Patel S, Benjamin R . Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer. 2003; 97(10):2544-53. DOI: 10.1002/cncr.11367. View

14.

Antonescu C, Elahi A, Healey J, Brennan M, Lui M, Lewis J . Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements. Clin Cancer Res. 2000; 6(7):2788-93. View

15.

Perez-Mancera P, Sanchez-Garcia I . Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model. Semin Cancer Biol. 2005; 15(3):206-14. DOI: 10.1016/j.semcancer.2005.01.006. View

16.

Castriota G, Thompson G, Lin Y, Scherer P, Moller D, Berger J . Peroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoprotein. Cell Biol Int. 2007; 31(6):586-91. DOI: 10.1016/j.cellbi.2006.11.033. View

17.

van der Graaf W, Blay J, Chawla S, Kim D, Bui-Nguyen B, Casali P . Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012; 379(9829):1879-86. DOI: 10.1016/S0140-6736(12)60651-5. View

18.

Juven-Gershon T, Oren M . Mdm2: the ups and downs. Mol Med. 1999; 5(2):71-83. PMC: 2230410. View

19.

Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M . Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009; 8(2):449-57. DOI: 10.1158/1535-7163.MCT-08-0848. View

20.

Rapp T, Yang L, Conrad 3rd E, Mandahl N, Chansky H . RNA splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid liposarcoma cells. J Orthop Res. 2002; 20(4):723-9. DOI: 10.1016/S0736-0266(02)00006-2. View